Judging quality and coordination in biomarker diagnostic development

Theoria (Spain)

Volumn 30, Issue 2, 2015, Pages 207-227

  Hey, Spencer Phillips ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Biomarkers; Neurooncology; Personalized medicine; Underdetermination

Indexed keywords

EID: 84932103040     PISSN: 04954548     EISSN: 2171679X     Source Type: Journal    
DOI: 10.1387/theoria.12697     Document Type: Article

References (75)

1. Abhinav, K., K. Aquilina, H. Gbejuade, M. La, K. Hopkins and V. Iyer. 2013. A Pilot Study of Glioblastoma Multiforme in Elderly Patients: Treatments, O-6-methylguanine-DNA Methyltransferase (MGMT) Methylation Status and Survival. Clinical Neurology and Neurosurgery 115 (8): 1375-1378.
2. Anderson, James A. 2006. The Ethics and Science of Placebo-controlled Trials: Assay Sensitivity and the Duhem-Quine Thesis. Journal of Medicine and Philosophy 31 (1): 65-81.
3. Ang, C., M.-C. Guiot, A. Ramanakumar, D. Roberge, and P. Kavan. 2010. Clinical Significance of Molecular Biomarkers in Glioblastoma. The Canadian Journal of Neurological Sciences 37 (5): 625-630.
4. Ariew, Roger. 1984. The Duhem Thesis. The British Journal for the Philosophy of Science 35 (4): 313-325.
5. Ashcroft, Richard E. 2004. Current Epistemological Problems in Evidence Based Medicine. Journal of Medical Ethics 30 (2): 131-135.
6. Balana, Carmen, Cristina Carrato, Jose Luis Ramirez, Andres Felipe Cardona, Mireia Berdiel, Jose Javier Sanchez, Miquel Taron et al. 2011. Tumour and Serum MGMT Promoter Methylation and Protein Expression in Glioblastoma Patients. Clinical and Translational Oncology 13 (9): 677-685.
7. Boucher, Helen W., George H. Talbot, John S. Bradley, John E. Edwards, David Gilbert, Louis B. Rice, Michael Scheld, Brad Spellberg, and John Bartlett. 2009. Bad Bugs, No Drugs: No Eskape! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases 48 (1): 1-12.
8. Brandes, Alba A., Enrico Franceschi, Alicia Tosoni, Francesca Benevento, Luciano Scopece, Valeria Mazzocchi, Antonella Bacci, Raffaele Agati, Fabio Calbucci, and Mario Ermani. 2009. Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients with Glioblastoma. Cancer 115 (15): 3512-3518.
9. Brandes, Alba A., Enrico Franceschi, Alicia Tosoni, Valeria Blatt, Annalisa Pession, Giovanni Tallini, Roberta Bertorelle et al. 2008. MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. Journal of Clinical Oncology 26 (13): 2192-2197.
10. Chan, D., M. Kam, B. Ma, S. Ng, J. Pang, C. Lau, D. Siu, B. Ng, X. Zhu, G. Chen, et al. 2011. Association of Molecular Marker O (6) Methylguanine DNA Methyltransferase and Concomitant Chemoradiotherapy with Survival in Southern Chinese Glioblastoma Patients. Hong Kong Medical Journal= Xianggang yi xue za zhi/Hong Kong Academy of Medicine 17 (3): 184-188.
11. Chin-Yee, Benjamin H. 2014. Underdetermination in Evidence-based Medicine. Journal of evaluation in clinical practice 20 (6): 921-927.
12. Chinot, Olivier L., Maryline Barrie, Stephane Fuentes, Nathalie Eudes, Sophie Lancelot, Philippe Metellus, Xavier Muracciole et al. 2007. Correlation Between O6-methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated with Neoadjuvant Temozolomide. Journal of Clinical Oncology 25 (12): 1470-1475.
13. Christians, Arne, Christian Hartmann, Axel Benner, Jochen Meyer, Andreas von Deimling, Michael Weller, Wolfgang Wick, and Markus Weiler. 2012. Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial On Newly Diagnosed Glioblastoma. PLoS One 7 (3): E33449.
14. Chung, Ki Young, Jinru Shia, Nancy E Kemeny, Manish Shah, Gary K Schwartz, Archie Tse, Audrey Hamilton, Dorothy Pan, Deborah Schrag, Lawrence Schwartz, et al. 2005. Cetuximab Shows Activity in Colorectal Cancer Patients with Tumors That Do Not Express the Epidermal Growth Factor Receptor By Immunohistochemistry. Journal of Clinical Oncology 23 (9): 1803-1810.
15. Clarke, Jennifer L., Fabio M Iwamoto, Joohee Sul, Katherine Panageas, Andrew B Lassman, Lisa M DeAngelis, Adília Hormigo, Craig P Nolan, Igor Gavrilovic, Sasan Karimi, et al. 2009. Randomized Phase II Trial of Chemoradiotherapy Followed By Either Dose-dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology 27 (23): 3861-3867.
16. Costa, Bruno M., Cláudia Caeiro, Inês Guimarães, Olga Martinho, Teresa Jaraquemada, Isabel Augusto, L Osório, P Linhares, M Honavar, M Resende, et al. 2010. Prognostic Value of MGMT Promoter Methylation in Glioblastoma Patients Treated with Temozolomide-based Chemoradiation: A Portuguese Multicentre Study. Oncology Reports 23 (6): 1655-1662.
17. Cunningham, David, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, et al. 2004. Cetuximab Monotherapy and Cetux-imab Plus Irinotecan in Irinotecan-refractory Metastatic Colorectal Cancer. New England Journal of Medicine 351 (4): 337-345.
18. Darling, Karen M. 2002. The Complete Duhemian Underdetermination Argument: Scientific Language and Practice. Studies In History and Philosophy of Science Part A 33 (3): 511-533.
19. Dunn, J., A. Baborie, F. Alam, K. Joyce, M. Moxham, R. Sibson, D. Crooks, D. Husband, A. Shenoy, A. Brodbelt et al. 2009. Extent of MGMT Promoter Methylation Correlates with Outcome in Glioblastomas Given Temozolomide and Radiotherapy. British Journal of Cancer 101 (1): 124-131.
20. Esteller, Manel, Jesus Garcia-Foncillas, Esther Andion, Steven N Goodman, Oscar F. Hidalgo, Vicente Vanaclocha, Stephen B. Baylin, and James G. Herman. 2000. Inactivation of the DNA-repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents. New England Journal of Medicine 343 (19): 1350-1354.
21. Febbo, Phillip G., Marc Ladanyi, Kenneth D. Aldape, Angelo M. De Marzo, M. Elizabeth Hammond, Daniel F Hayes, A. John Iafrate, R. Kate Kelley, Guido Marcucci, Shuji Ogino, et al. 2011. NCCN Task Force Report: Eval-uating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network 9 (Suppl 5): S-1.
22. Giacomini, Mita. 2009. Theory-based Medicine and the Role of Evidence: Why the Emperor Needs New Clothes, Again. Perspectives in Biology and Medicine 52 (2): 234-251.
23. Gilbert, Mark R., Meihua Wang, Kenneth D. Aldape, Roger Stupp, Monika E. Hegi, Kurt A. Jaeckle, Terri S. Armstrong, Jeffrey S. Wefel, Minhee Won, Deborah T. Blumenthal et al. 2013. Dose-dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology 31 (32): 4085-4091.
24. Glasziou, Paul, Douglas G. Altman, Patrick Bossuyt, Isabelle Boutron, Mike Clarke, Steven Julious, Susan Michie, David Moher and Elizabeth Wager. 2014. Reducing Waste from Incomplete or Unusable Reports of Biomedical Research. The Lancet 383 (9913): 267-276.
25. Gutenberg, A., H. C. Bock, W. Brück, L. Doerner, H. M. Mehdorn, W. Roggendorf, M. Westphal, J. Felsberg, G. Reifenberger and A. Giese. 2013. MGMT Promoter Methylation Status and Prognosis of Patients with Primary or Recurrent Glioblastoma Treated with Carmustine Wafers. British Journal of Neurosurgery 27 (6): 772-778.
26. Hay, Michael, David W. Thomas, John L. Craighead, Celia Economides and Jesse Rosenthal. 2014. Clinical Development Success Rates for Investigational Drugs. Nature Biotechnology 32 (1): 40-51.
27. Hayes, Daniel F., Jef Allen, Carolyn Compton, Gary Gustavsen, Debra G. B. Leonard, Robert McCormack, Lee Newcomer, Kristin Pothier, David Ransohof, Richard L. Schilsky, Ellen Sigal, Sheila E. Taube and Sean R. Tunis. 2013. Breaking a Vicious Cycle. Science Translational Medicine 5 (196): 196cm6.
28. Hegi, Monika E., Annie-Claire Diserens, Sophie Godard, Pierre-Yves Dietrich, Luca Regli, Sandrine Ostermann, Philippe Otten, Guy Van Melle, Nicolas de Tribolet and Roger Stupp. 2004. Clinical Trial Substantiates the Predictive Value of O-6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide. Clinical Cancer Research 10 (6): 1871-1874.
29. Hegi, Monika E., Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M. Kros, Johannes A. Hainfellner, Warren Mason, Luigi Mariani et al. 2005. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine 352 (10): 997-1003.
30. Herrlinger, Ulrich, Johannes Rieger, Dorothee Koch, Simon Loeser, Britta Blaschke, Rolf-Dieter Kortmann, Joachim P. Steinbach, Thomas Hundsberger, Wolfgang Wick, Richard Meyermann et al. 2006. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. Journal of Clinical Oncology 24 (27): 4412-4417.
31. Hey, Spencer Phillips, Charles M. Heilig and Charles Weijer. 2013. Accumulating Evidence and Research Organization (AERO) Model: A New Tool for Representing, Analyzing, and Planning a Translational Research Program. Trials 14: 159.
32. Hey, Spencer Phillips and Charles Weijer. 2013. Assay Sensitivity and the Epistemic Contexts of Clinical Trials. Perspectives in Biology and Medicine 56 (1): 1-17.
33. Hey, Spencer Phillips. 2014. Theory Testing and Implication in Clinical Trials. In Philosophy of Science Association 24th Biennial Meeting.
34. - 2015. Robust and Discordant Evidence: Methodological Lessons from Clinical Research. Philosophy of Science 82 (1): 55-75.
35. Hey, Spencer Phillips and Jonathan Kimmelman. 2014. The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials. Kennedy Institute of Ethics Journal 24 (2): 121-139.
36. Howick, J. 2009. Questioning the Methodologic Superiority of 'Placebo' Over 'Active' Controlled Trials. The American Journal of Bioethics 9: 34-48.
37. Howick, Jeremy. 2011. Exposing the Vanities -and A Qualified Defense- of Mechanistic Reasoning in Health Care Decision Making. Philosophy of Science 78 (5): 926-940.
38. Howson, Colin and Peter Urbach. 2006. Scientific Reasoning: The Bayesian Approach. Open Court Publishing.
39. Hsu, Chih-Yi, Shih-Chieh Lin, Hsiang-Ling Ho, Yi-Chun Chang-Chien, Sanford P-C Hsu, Yu-Shu Yen, Ming-Hsiung Chen, Wan-You Guo and Donald M-T Ho. 2013. Exclusion of Histiocytes/Endothelial Cells and Using Endothelial Cells as Internal Reference are Crucial for Interpretation of MGMT Immunohistochemistry in Glioblastoma. American Journal of Surgical Pathology 37 (2): 264-271.
40. Iliadis, Georgios, Vassiliki Kotoula, Athanasios Chatzisotiriou, Despina Televantou, Anastasia G. Eleftheraki, Sofia Lambaki, Despina Misailidou, Panagiotis Selviaridis and George Fountzilas. 2012. Volumetric and MGMT Parameters in Glioblastoma Patients: Survival Analysis. BMC Cancer 12 (1): 3.
41. Karim, Khaled Abdel, M. M. El Mahdy, M. M. Abdel Wahab, L. R. Ezz El Arab, A. El Shehaby and S. Abdel Raouf. 2012. Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Patients: O6-methylguanine-DNA Methyltransferase (MGMT) Promotor Methylation Status and Ki-67 as Biomarkers for Survival and Response to Treatment. The ChineseGerman Journal of Clinical Oncology 11 (3): 168-176.
42. Kim, Young Suk, Se Hoon Kim, Jaeho Cho, Jun Won Kim, Jong Hee Chang, Dong Suk Kim, Kyu Sung Lee and Chang-Ok Suh. 2012. MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide-based Chemoradiotherapy: A Single-institution Study. International Journal of Radiation Oncology Biology Physics 84 (3): 661-667.
43. Kimmelman, Jonathan and Alex John London. 2015. The Structure of Clinical Translation: Efficiency, Information, and Ethics. Hastings Center Report 45: 1-7.
44. Kimmelman, Jonathan, Jeffrey S. Mogil and Ulrich Dirnagl. 2014. Distinguishing Between Exploratory and Confirmatory Preclinical Research Will Improve Translation. PLoS Biology 12 (5): E1001863.
45. Kyzas, Panayiotis A., Konstantinos T. Loizou and John P. A. Ioannidis. 2005. Selective Reporting Biases in Cancer Prognostic Factor Studies. Journal of the National Cancer Institute 97 (14): 1043-1055.
46. Lalezari, Shadi, Arthur P. Chou, Anh Tran, Orestes E. Solis, Negar Khanlou, Weidong Chen, Sichen Li, Jose A. Carrillo, Reshmi Chowdhury, Julia Selfridge et al. 2013. Combined Analysis of O6-methylguanine-DNA Methyltransferase Protein Expression and Promoter Methylation Provides Optimized Prognostication of Glioblastoma Outcome. Neuro-oncology 15 (3): 370-381.
47. Lam, Nadine and Carole R. Chambers. 2012. Temozolomide Plus Radiotherapy for Glioblastoma in a Canadian Province: Efficacy Versus Effectiveness and the Impact of O6-methylguanine-DNA-methyltransferase Promoter Methylation. Journal of Oncology Pharmacy Practice 18 (2): 229-238.
48. Lechapt-Zalcman, Emmanuèle, Guénäelle Levallet, Audrey Emmanuelle Dugué, Anne Vital, Marie-Danièle Diebold, Philippe Menei, Philippe Colin, Philippe Peruzzy, Evelyne Emery, Myriam Bernaudin et al. 2012. O6-methylguanine-DNA methyltransferase (MGMT) Promoter Methylation and Low MGMT-encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants After Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide. Cancer 118 (18): 4545-4554.
49. Mallett, S., A. Timmer, W. Sauerbrei and D. G. Altman. 2009. Reporting of Prognostic Studies of Tumour Markers: A Review of Published Articles in Relation to REMARK Guidelines. British Journal of Cancer 102 (1): 173-180.
50. McDonald, K. L., R. W. Rapkins, J. Olivier, L. Zhao, K. Nozue, D. Lu, S. Tiwari, J. Kuroiwa-Trzmielina, J. Brewer, H. R. Wheeler et al. 2013. The T Genotype of the MGMT C > T (rs16906252) Enhancer Single-nucleotide Polymorphism (SNP) Is Associated with Promoter Methylation and Longer Survival in Glioblastoma Patients. European Journal of Cancer 49 (2): 360-368.
51. McShane, Lisa M., Douglas G. Altman, Willi Sauerbrei, Sheila E. Taube, Massimo Gion, Gary M. Clark et al. 2005. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Journal of the National Cancer Institute 97 (16): 1180-1184.
52. McShane, Lisa M. and Mei-Yin C. Polley. 2013. Development of Omics-based Clinical Tests for Prognosis and Therapy Selection: The Challenge of Achieving Statistical Robustness and Clinical Utility. Clinical Trials, 10 (5): 653-665.
53. Mellai, Marta, Valentina Caldera, Laura Annovazzi, Adriano Chiò, Michele Lanotte, Paola Cassoni, Gaetano Finocchiaro and Davide Schiffer. 2009. MGMT Promoter Hypermethylation In a Series of 104 Glioblastomas. Cancer Genomics-Proteomics 6 (4): 219-227.
54. Motomura, Kazuya, Atsushi Natsume, Yugo Kishida, Hiroyuki Higashi, Yutaka Kondo, Yoko Nakasu, T atsuya Abe, Hiroki Namba, Kenji Wakai and Toshihiko Wakabayashi. 2011. Benefits of Interferon-β and Temozolomide Combination Therapy for Newly Diagnosed Primary Glioblastoma with the Unmethylated MGMT Promoter. Cancer 117 (8): 1721-1730.
55. NCCN et al. 2012. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2. 2013.
56. Needham, Paul. 2000. Duhem and Quine. Dialectica 54 (2): 109-132.
57. Panet-Raymond, Valerie, Luis Souhami, David Roberge, Petr Kavan, Lily Shakibnia, Thierry Muanza, Christine Lambert, Richard Leblanc, Rolando Del Maestro, Marie-Christine Guiot et al. 2009. Accelerated Hypofractionated Intensity-modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Patients with Glioblastoma Multiforme: A Safety and Efficacy Analysis. International Journal of Radiation Oncology∗ Biology∗ Physics 73 (2): 473-478.
58. Park, Chul-Kee, JinWook Kim, Su Youn Yim, Ah Reum Lee, Jung Ho Han, Chae-Yong Kim, Sung-Hye Park, Tae Min Kim, Se-Hoon Lee, Seung Hong Choi et al. 2011. Usefulness of MS-MLPA for Detection of MGMT Promoter Methylation in the Evaluation of Pseudoprogression in Glioblastoma Patients. Neuro-oncology 13 (2): 195-202.
59. Pazdur, Richard. 2013. FDA Approval for Temozolomide. Http://www.cancer.gov/cancertopics/druginfo/fda-temozolomide (retrieved August 7, 2014). Quillien, Véronique, Audrey Lavenu, Lucie Karayan-Tapon, Catherine Carpentier, Marianne Labussière, Thierry Lesimple, Olivier Chinot, Michel Wager, Jérome Honnorat, Stephan
60. Saikali et al. 2012. Comparative Assessment of 5 methods (Methylation-specific Polymerase Chain Reaction, Methylight, Pyrosequencing, Methylation-sensitive High-resolution Melting, and Immunohistochemistry) to Analyze O6-methylguanine-DNA-methyltranferase in a Series of 100 Glioblastoma Patients. Cancer 118 (17): 4201-4211.
61. Reifenberger, Guido, Bettina Hentschel, Jörg Felsberg, Gabriele Schackert, Matthias Simon, Oliver Schnell, Manfred Westphal, Wolfgang Wick, Torsten Pietsch, Markus Loeffler et al. 2012. Predictive Impact of MGMT Promoter Methylation in Glioblastoma of the Elderly. International Journal of Cancer 131 (6): 1342-1350.
62. Romano, Andrea, L. F. Calabria, F. Tavanti, G. Minniti, M. C. Rossi-Espagnet, V. Coppola, S. Pugliese, D. Guida, G. Francione, C. Colonnese et al. 2013. Apparent Diffusion Coefficient Obtained By Magnetic Resonance Imaging as a Prognostic Marker in Glioblastomas: Correlation with MGMT Promoter Methylation Status. European Radiology 23 (2): 513-520.
63. Seymour, L., S. P. Ivy, D. Sargent, D. Spriggs, L. Baker, L. Rubinstein, M. J. Ratain, M. Le Blanc, D. Stewart, J. Crowley, S. Groshen, J. S. Humphrey, P. West and D. Berry. 2010. The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research 16: 1764-1769.
64. Shah, Nameeta, Biaoyang Lin, Zita Sibenaller, Timothy Ryken, Hwahyung Lee, Jae-Geun Yoon, Steven Rostad and Greg Foltz. 2011. Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM. PloS One, 6 (1): E16146.
65. Simon, Richard. 2012. Clinical Trials for Predictive Medicine. Statistics in Medicine 31 (25): 3031-3040.
66. Simon, Richard M., Soonmyung Paik and Daniel F. Hayes. 2009. Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. Journal of the National Cancer Institute 101 (21): 1446-1452.
67. Stupp, Roger, Warren P. Mason, Martin J. Van Den Bent, Michael Weller, Barbara Fisher, Martin J. B. Taphoorn, Karl Belanger, Alba A. Brandes, Christine Marosi, Ulrich Bogdahn et al. 2005. Radio therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine 352 (10): 987-996.
68. Sunwoo, Leonard, Seung Hong Choi, Chul-Kee Park, Jin Wook Kim, Kyung Sik Yi, Woong Jae Lee, Tae Jin Yoon, Sang Woo Song, Ja Eun Kim, Ji Young Kim et al. 2013. Correlation of Apparent Diffusion Coefficient Values Measured By Diffusion MRI and MGMT Promoter Methylation Semiquantitatively Analyzed with MS-MLPA in Patients with Glioblastoma Multiforme. Journal of Magnetic Resonance Imaging 37 (2): 351-358.
69. Thon, Niklas, Sabina Eigenbrod, Eva M. Grasbon-Frodl, Juergen Lutz, Simone Kreth, Gabriele Popperl, Claus Belka, Hans A. Kretzschmar, Joerg-Christian Tonn and Friedrich W. Kreth. 2011. Predominant Influence of MGMT Methylation in Non-resectable Glioblastoma After Radiotherapy Plus temozolomide. Journal of Neurology, Neurosurgery & Psychiatry 82: 441-446.
70. Tunis, Sean R., Daniel B. Stryer and Carolyn M. Clancy. 2003. Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy. Journal of the American Medical Association 290 (12): 1624-1632.
71. Watanabe, Reiko, Yoko Nakasu, Hiroshi Tashiro, Koichi Mitsuya, Ichiro Ito, Satoshi Nakasu and Takashi Nakajima. 2011. O6-methylguanine DNA Methyltransferase Expression in Tumor Cells Predicts Outcome of Radiotherapy Plus Concomitant and Adjuvant Temozolomide Therapy in Patients with Primary Glioblastoma. Brain Tumor Pathology 28 (2): 127-135.
72. Weiler, Markus, Christian Hartmann, Dorothee Wiewrodt, Ulrich Herrlinger, Thierry Gorlia, Oliver Bähr, Richard Meyermann, Michael Bamberg, Marcos Tatagiba, Andreas von Deimling et al. 2010. Chemoradiotherapy of Newly Diagnosed Glioblastoma with Intensified Temozolomide. International Journal of Radiation Oncology∗ Biology∗ Physics 77 (3): 670-676.
73. Weller, Michael, Jörg Felsberg, Christian Hartmann, Hilmar Berger, Joachim P Steinbach, Johannes Schramm, Manfred Westphal, Gabriele Schackert, Matthias Simon, Jörg C. Tonn et al. 2009. Molecular Predictors of Progression-free and Overall Survival in Patients with Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology 27 (34): 5743-5750.
74. Wick, Wolfgang, Michael Weller, Martin van den Bent, Marc Sanson, Markus Weiler, Andreas von Deimling, Christoph Plass, Monika Hegi, Michael Platten and Guido Reifenberger. 2014. MGMT Testing- The Challenges for Biomarker-based Glioma Treatment. Nature Reviews Neurology 10: 372-385.
75. Worrall, John. 2010. Evidence: Philosophy of Science Meets Medicine. Journal of Evaluation in Clinical Practice 16: 356-362.